Commercialization Strategy with a Biotech Legend
We're excited to offer our network of founders and investors in life sciences access to an exclusive conversation with Scott Shively, a powerhouse in the pharmaceutical industry with a proven track record in commercialization, business development, and capital raising. From leading companies like Bexion Pharmaceuticals and Neumentum to key roles at Pfizer and Sanofi-Aventis, Scott has driven groundbreaking therapies and led successful launches for major brands like Lidoderm, Flector Patch, Lyrica, Celebrex, and Nucynta/Nucynta ER among many others. Don’t miss this chance to gain insights from a commercialization expert who's been on the ground floor of dozens of launches.
To read more about Scott's background:
Scott is an experienced executive leader in the US and international pharmaceutical markets with extensive Founder, CEO, and CCO experience. He has deep expertise in executive leadership, business development/M&As transactions, capital raising, early and late stage drug development, commercial execution and international business, with demonstrated ability to lead, rapidly create and grow organizations, raise capital, develop strategy and execute to deliver results and drive rapid growth in value for shareholders.
Scott was most recently President & CEO of Bexion Pharmaceuticals, a clinical-stage private biopharmaceutical company developing a new generation of biologic immunotherapies to treat cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN). Previous to that he co-founded and led four successful funding rounds for Neumentum, Inc., a private biopharma company with a Pain & CNS footprint, dedicated to developing and commercializing non-opioid pain products.
Over the course of his career, Scott has achieved outstanding financial results and growth in value for shareholders by developing innovative strategies, acquiring assets, building highly talented teams, successfully launching new products, and executing to exceed goals. He has extensive experience with “Big Pharma” companies such as Pfizer and Sanofi-Aventis, and has also has also had C-suite roles for rapid-growth specialty companies such as Endo, Alpharma, and Depomed. He has an impressive track record of successful launches and driving growth for brands such as Lidoderm, Flector Patch, Lyrica, Celebrex, and Nucynta/Nucynta ER among many others.
Scott is equally comfortable leading a US or International business, and has had extensive background in all of the major global markets during his career.